Immunization Newsbriefs © Copyright Information Inc., Bethesda, MD. Brought to you by the National Network for Immunization Information (NNii). Visit NNii’s new website at http://www.immunizationinfo.org.

July 16, 2001

“16,000 in Largest HIV-Vaccine Trial”

Nation (Thailand) (www.nationmultimedia.com) (07/16/01)

Thailand’s Public Health Ministry reports that 16,000 HIV-negative volunteers between the ages of 20 and 30 years old will participate in a phase III trial of an experimental HIV vaccine.  Participants in the three-year study will undergo a six-month regimen of ALVAC-HIV (vVP1521) shots, boosted twice with AIDSvax (rGP120 B/E), designed to stimulate the humoral antibodies and cell-mediated immunity needed in order to block HIV.  ALVAC is made by inserting a portion of the HIV gene into the canary-pox virus.  Trial volunteers will be selected from eight districts within the high-risk provinces of Chon Buri and Rayong, where the infection rate of HIV is especially high.  Phase III is a collaborative effort between the Thai health ministry, Mahidol University and the U.S. Army’s office of the Surgeon General.  The Phase I and II vaccine trials for safety and immunity efficacy were conducted jointly by Mahidol University, Siriraj Hospital and Chiang Mai University Research Institute in Health Sciences.

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.